NCT03134027 (Immune PDX) is a clinical trial of Bone marrow biopsy in Genito Urinary Cancer, sponsored by Duke University.

Who is sponsoring NCT03134027?

NCT03134027 is sponsored by Duke University.

What drugs are being tested in NCT03134027?

Interventions in NCT03134027: Bone marrow biopsy, Tumor biopsy.

What condition does NCT03134027 study?

NCT03134027 studies Genito Urinary Cancer, Bladder Cancer, Kidney Cancer, Prostate Cancer.

Is NCT03134027 still recruiting?

NCT03134027 is currently terminated. Last updated 18 July 2024.

Last reviewed 2024-07-18 · How we verify

NCT03134027: Immune PDX

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary (GU) Cancers

Terminated Last updated 18 July 2024

What this trial tests

trial testing Bone marrow biopsy in Genito Urinary Cancer in 3 participants. Terminated before completion.

Timeline

19 October 2017

Primary endpoint
9 May 2018

9 May 2018

Quick facts

Lead sponsor	Duke University
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	3
Start date	19 October 2017
Primary completion	9 May 2018
Estimated completion	9 May 2018
Sites	1 location across United States

Drugs / interventions tested

Bone marrow biopsy
Tumor biopsy

Conditions studied

Genito Urinary Cancer — all drugs for Genito Urinary Cancer →
Bladder Cancer — all drugs for Bladder Cancer →
Kidney Cancer — all drugs for Kidney Cancer →
Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Duke University

Who can join

18 and older, any sex, with Genito Urinary Cancer or Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to obtain human blood CD34+ hematopoietic stem/progenitor cells (HSPCs) to reconstitute a match human immune system in our PDX model. The hypothesis is that by using matched leukocytes and PDX from the same patient, rejection of the PDX by the host immune system will not be observed and therefore a preclinical model to study immunotherapy can be developed to study, understand and improve upon our current therapies. HSPCs will be collected from bone marrow aspirate obtained from a bone marrow biopsy. The secondary objective is to use patient tumor biopsy samples or circulating tumor cell samples to develop additional preclinical models of GU cancers, particularly prostate cancer, that are clinically relevant by generating additional PDXs.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Role of Patient-Derived Models of Cancer in Translational Oncology.
Idrisova KF, Simon HU, Gomzikova MO. · · 2022 · cited 53× · PMID 36612135 · DOI 10.3390/cancers15010139
Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research.
Inoue A, Deem AK, Kopetz S, Heffernan TP, et al · · 2019 · cited 31× · PMID 31500168 · DOI 10.3390/cancers11091321
Harnessing PDX and PDX 2.0: the next-generation paradigm for precision oncology and translational breakthroughs.
Jian C, Fu H, Wu W, Zhang N, et al · · 2026 · PMID 41699647 · DOI 10.1186/s12943-026-02594-w

Verify or expand the search:

Other trials of Bone marrow biopsy

Trials testing the same drug.

NCT05918055 — Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes · Phase 1, PHASE2 · terminated
NCT03448393 — CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-ex · Phase 1 · completed
NCT02911142 — Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated La · Phase 1, PHASE2 · active not recruiting
NCT02995655 — CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Le · Phase 1 · completed
NCT02416908 — Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia · Phase 1, PHASE2 · completed

Other recruiting trials for Genito Urinary Cancer

Currently open trials in the same condition.

NCT06717711 — Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genit · Phase 3 · recruiting

Other Duke University trials

Trials by the same sponsor.

NCT07216456 — Vaginal Dilator Therapy After Pelvic Radiation · NA · not yet recruiting
NCT07519317 — Dosing and Deployment Trial: A Home-based Optokinetic Treatment · NA · not yet recruiting
NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
NCT07216963 — The Community Paramedic Response and Overdose Outreach With Supportive Medical-Legal Services Study · NA · not yet recruiting
NCT07459218 — IDEAS for Hope to Reduce Suicide Risk and Improve HIV Care Engagement in Tanzania · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03134027 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Duke University
Last refreshed: 18 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03134027.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing